

Optibrium appoints Steve Yemm as Chief Commercial Officer

- *New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team*
- *Latest in a series of senior hires as the Company continues its rapid growth trajectory*

CAMBRIDGE, UK 17 January 2023 – Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Steve Yemm as Chief Commercial Officer (CCO), the latest in a series of senior-level hires as the Company rapidly expands. With over 30 years' experience in informatics and life sciences, Steve brings an extensive sales and marketing record that will be instrumental to the continued global commercialisation and adoption of Optibrium's innovative computational and AI drug discovery technologies.

As CCO, Steve will manage the commercial team to drive forward global sales, customer success and marketing activities, as well as working within Optibrium's executive team to develop commercial strategy.

Steve joins Optibrium from Paradigm4, a company focused on transforming how multi-dimensional scientific data is integrated, shared, and analysed, where he was VP of Sales for Life Sciences and Healthcare. Steve has held numerous senior positions at companies delivering SaaS software solutions to the biotechnology, pharmaceutical and life science industries, leading on global deals throughout his career. Prior roles include CCO of Aigenpulse, a data management and machine learning platform for life sciences, and Chief Executive Officer at BioData, a digital science company providing cloud- and web-based lab informatics solutions. With industry experience as a research scientist and a BSc in Applied Chemistry from the University of Nottingham, Steve has a proven scientific background to complement his business acumen.

Steve Yemm, Chief Commercial Officer, Optibrium, said: "Optibrium continues to demonstrate its position at the forefront of the drug discovery industry as a provider of innovative AI and software solutions, with real potential to improve the drug discovery process. I am delighted to be joining the team at such a dynamic phase of its commercial growth."

Matthew Segall, Chief Executive Officer, Optibrium, commented: "We are pleased to welcome Steve to the Optibrium team. His impressive depth of both scientific and business experience will be invaluable in guiding the Company as it continues to go from strength to strength, reinforcing the position of our *in silico* technologies and AI platforms on the global stage."

For further information on Optibrium, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

ENDS

Notes to Editors:



Steve Yemm, CCO, Optibrium



Dr Matthew Segall, CEO, Optibrium

For high-resolution images, please email sarah.jeffery@zymecommunications.com.



To opt-out from receiving press releases from Zyme Communications, please email info@zymecommunications.com.
To view our privacy policy, please [click here](#).

Media contact

Esmé Walters
Zyme Communications
Email: esme.walters@zymecommunications.com
Phone: +44 (0)7377 543244

Optibrium

Michelle Harrison
Head of Strategic Marketing
Email: michelle@optibrium.com
Phone: +44 (0)1223 815903

About Optibrium

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company's Augmented Chemistry® products and services, including Cerella™, deliver proven artificial intelligence technologies that continuously learn from all available data to supplement researchers' experience and skills.

Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with a US subsidiary, Optibrium Inc., based in Cambridge MA. The company works closely with over 170 customers and collaborators worldwide, including leading global pharma, biotech, agrochemical and flavouring companies and not-for-profit and academic groups.

For further information, visit www.optibrium.com.